Loading…
Jasper Therapeutics, Inc. is projected to rise to $0.6298 by 2027, a +9% move from its current price of $0.5795. JSPR is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $0.5388 | $0.5799 | $0.6241 | +0.06% |
| Jul 14 | $0.5229 | $0.5802 | $0.6438 | +0.12% |
| Jul 15 | $0.5112 | $0.5806 | $0.6594 | +0.19% |
| Jul 16 | $0.5015 | $0.5809 | $0.6729 | +0.25% |
| Jul 17 | $0.4932 | $0.5813 | $0.6851 | +0.31% |
| Jul 18 | $0.4858 | $0.5817 | $0.6964 | +0.37% |
| Jul 19 | $0.4792 | $0.582 | $0.707 | +0.44% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.4792 | $0.582 | $0.707 | +0.44% |
| Week 2 | $0.444 | $0.5846 | $0.7696 | +0.88% |
| Week 3 | $0.4193 | $0.5871 | $0.8222 | +1.32% |
| Week 4 | $0.3997 | $0.5897 | $0.87 | +1.76% |
| Week 5 | $0.3835 | $0.5923 | $0.9149 | +2.21% |
| Week 6 | $0.3695 | $0.5949 | $0.9578 | +2.65% |
| Week 7 | $0.3572 | $0.5975 | $0.9994 | +3.10% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapeutics targeting mast stem cell driven diseases in the United States. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells.
Founded in 2018 and headquartered in Redwood City, California, Jasper Therapeutics operates in the Healthcare sector. The company concentrates on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma.
Jasper Therapeutics, Inc. trades under the symbol JSPR. The current price is $0.5814 and the market cap is $16.28M. It holds a rank of 4987 in market capitalization.
The asset is categorized in Healthcare. The price outlook reflects a multi-year forecast with varying yearly averages and sentiment. The near-term expected average price for 2026 is $0.5814 (sentiment Neutral), with a sequence of years showing both modest gains and occasional declines before a longer-term upside into the 2030s and beyond.
From 2026 through 2050, the forecast projects a path that includes a bear phase around 2030–2031, followed by a shift toward neutral and bullish years, culminating in higher average prices by 2040 and 2050. Specific yearly averages and corresponding ROI show a mix of flat, negative, and positive returns across the horizon.
A major floor 90.6% below — a decisive break under it would weaken the trend.
The nearest floor, 41.2% below — buyers have tended to step in here.
The nearest ceiling, 53.6% above — a clean break opens room to run.
A major ceiling 145.0% above — clearing it would confirm fresh momentum.
Key JSPR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of JSPR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.5248 | Buy | $0.5339 | Buy |
| MA 10 | $0.4689 | Buy | $0.5033 | Buy |
| MA 20 | $0.4697 | Buy | $0.5092 | Buy |
| MA 50 | $0.6653 | Sell | $0.6421 | Sell |
| MA 100 | $0.8898 | Sell | $0.91 | Sell |
| MA 200 | $1.39 | Sell | $1.85 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 55.17 | Neutral |
| Stoch RSI (14) | 99.62 | Sell |
| CCI (20) | 201.78 | Buy |
| Williams %R (14) | -0.42 | Info |
| MACD (12,26,9) | 0.03 | Buy |
| ROC (12) | 18.61 | Buy |
| Bollinger %B (20,2) | 1.03 | Sell |
| Stochastic %K (14) | 99.58 | Sell |
| TRIX (15) | -1.63 | Sell |
| Awesome (5,34) | -0.03 | Sell |
| Ultimate (7,14,28) | 72.97 | Sell |
| Momentum (10) | 0.14 | Buy |
| Aroon Osc (25) | 32.00 | Buy |
| Hull MA (9) | 0.58 | Buy |
| ADX (14) | 25.33 | Buy |
| ATR (14) | 0.03 | Info |
The 30-day technical picture presents NEUTRAL sentiment with an RSI of 60. This indicates limited upside momentum over the near term.
Two widely watched moving averages place the near-term context: SMA50 at $0.6723 and SMA200 at $1.40. These levels help define near-term support and resistance dynamics and frame potential momentum changes.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.341 | $0.5795 | $0.81 | 0% | Neutral | |
| $0.457 | $0.6298 | $0.9385 | +9% | Neutral | |
| $0.3776 | $0.5531 | $0.8783 | -5% | Neutral | |
| $0.3679 | $0.5676 | $0.9462 | -2% | Neutral | |
| $0.2832 | $0.4581 | $0.7951 | -21% | Bearish | |
| $0.2745 | $0.464 | $0.8337 | -20% | Bearish | |
| $0.3878 | $0.6837 | $1.27 | +18% | Neutral | |
| $0.3799 | $0.6976 | $1.33 | +20% | Bullish | |
| $0.3862 | $0.7377 | $1.44 | +27% | Bullish | |
| $0.4027 | $0.7995 | $1.60 | +38% | Bullish | |
| $0.4926 | $1.09 | $2.40 | +89% | Bullish | |
| $0.6291 | $1.40 | $3.22 | +141% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.341 | $0.5795 | $0.716 | +0.00% |
| August 2026 | $0.511 | $0.6189 | $0.7806 | +6.79% |
| September 2026 | $0.4994 | $0.6134 | $0.79 | -0.88% |
| October 2026 | $0.4606 | $0.5727 | $0.7505 | -6.64% |
| November 2026 | $0.4584 | $0.5759 | $0.7657 | +0.56% |
| December 2026 | $0.4739 | $0.6013 | $0.81 | +4.41% |
Click any year to see its month-by-month JSPR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The JSPR price prediction for 2026 points to an average of $0.5795 (low $0.341, high $0.81) — a potential gain of 0% on today's $0.5795. Price action looks broadly range-bound.
In 2027, JSPR is projected to trade between $0.457 and $0.9385, averaging $0.6298 — a potential gain of +9% from today's $0.5795. That is up +9% on the projected 2026 average. A consolidation phase looks the most probable path here.
Jasper Therapeutics, Inc.'s 2028 outlook centres on $0.5531, within a $0.3776 to $0.8783 range. That is -12% versus the projected 2027 average. That marks a -5% change versus current levels. Price action looks broadly range-bound.
By 2029, JSPR could reach as high as $0.9462, with a base case around $0.5676 and support toward $0.3679 — roughly -2% from $0.5795. A consolidation phase looks the most probable path here.
Expect JSPR to range from $0.2832 to $0.7951 through 2030. The $0.4581 average target implies a -21% move from current prices. That is -19% versus the projected 2029 average. A cyclical pullback looks likely — prices rarely move in a straight line.
The JSPR price prediction for 2031 points to an average of $0.464 (low $0.2745, high $0.8337) — a potential decline of -20% on today's $0.5795. Expect choppier, lower action through this leg of the cycle.
In 2032, JSPR is projected to trade between $0.3878 and $1.27, averaging $0.6837 — a potential gain of +18% from today's $0.5795. That is up +47% on the projected 2031 average. Price action looks broadly range-bound.
Jasper Therapeutics, Inc.'s 2033 outlook centres on $0.6976, within a $0.3799 to $1.33 range. That is up +2% on the projected 2032 average. That marks a +20% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, JSPR could reach as high as $1.44, with a base case around $0.7377 and support toward $0.3862 — roughly +27% from $0.5795. Momentum favours further upside here.
Expect JSPR to range from $0.4027 to $1.60 through 2035. The $0.7995 average target implies a +38% move from current prices. That is up +8% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The JSPR price prediction for 2040 points to an average of $1.09 (low $0.4926, high $2.40) — a potential gain of +89% on today's $0.5795. Momentum favours further upside here.
In 2050, JSPR is projected to trade between $0.6291 and $3.22, averaging $1.40 — a potential gain of +141% from today's $0.5795. That is up +28% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in JSPR today (≈ 1,725.625539 JSPR) could be worth
$2,412.34
+$1,412.34 (+141%) by 2050 · US Dollar
Based on the average projected JSPR price of $1.4 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in JSPRwould be worth at today's price.
$1,000 invested in JSPR on Jul 10, 2025 (≈ 281.690145 JSPR) would be worth
$163.24
-$836.76 (-83.7%) today · 0.16× · US Dollar
Based on a JSPR entry price of $3.55 vs. today's $0.5795.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.428 | $1,353.97 | +35.4% |
| 1 month ago | $0.464 | $1,248.92 | +24.9% |
| 3 months ago | $0.802 | $722.57 | -27.7% |
| 6 months ago | $1.48 | $391.55 | -60.8% |
| 1 year ago | $3.55 | $163.24 | -83.7% |
| All time (5.0y) ago | $99.2 | $5.84 | -99.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our JSPR forecast.
Our base-case forecast reaches $1.20 around 2050.
Implied market cap at $1.20: $33.61M
The multi-year forecast shows a mixed path with notable inflection points. In 2026 the average is $0.5814 with ROI 0 and sentiment NEUTRAL. In 2027 the average rises to $0.6321 with ROI 8.7, while 2028 slides to $0.5575 with ROI -4.1 and 2029 edges up to $0.5689 with ROI -2.1, all amid NEUTRAL sentiment.
The outlook turns bearish in 2030 (avg $0.4585, ROI -21.1) and 2031 (avg $0.4673, ROI -19.6), before moving into neutral territory again in 2032 ($0.683 avg, ROI 17.5) and 2033 ($0.6949 avg, ROI 19.5). The trend shifts more clearly bullish from 2034 onward (2034 avg $0.741, ROI 27.4; 2035 avg $0.802, ROI 37.9). The long arc strengthens into higher-valued years with 2040 (avg $1.10, ROI 88.5) and 2050 (avg $1.39, ROI 139.8), both labeled BULLISH.
These figures imply a late-cycle upside despite earlier headwinds, with the strongest gains projected in the 2040s and beyond. As always, these are estimates and not guarantees, and actual results may differ due to market and company-specific developments.
Tap a question to reveal the answer.
The forecasted average price for 2030 is $0.4585, with a minimum of $0.2834 and a maximum of $0.7959. The ROI is -21.1 and the sentiment is BEARISH.
Near-term expectations show a flat to modest gain (2026 avg $0.5814, ROI 0; 2027 avg $0.6321, ROI 8.7). However, the forecast also includes bear years in 2030–2031 before a longer-term bullish trajectory later, so outcomes are mixed and uncertain.
Yes—the 2050 forecast maximum is $3.21, indicating the upper bound of the provided long-term projection.
Current price is $0.5814 and the market cap is $16.28M.
RSI14 is 60 with NEUTRAL sentiment. The SMA50 is $0.6723 and the SMA200 is $1.40. The 30-day range runs from $0.3528 to $0.9582, with support at $0.341 and resistance at $0.902.
Jasper Therapeutics, Inc. Community Discussion
0Share your Jasper Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.